Latest News
-
Honasa Consumer to Strengthen Operations by Merging Fusion Cosmeceutics and Just4Kids -
Wipro Reports 7.8% Decline in Q4 Net Profit; CEO Highlights Economic Challenges -
IREDA Hits Record Annual PAT of Rs 1,252 Cr in FY24; Q4 Profits Up by 33% -
Massive Employee Exodus Hits India's Top IT Companies in FY23-24 -
Air India Enhances Operational Efficiency with New Crew Management System -
BlackRock Acquires Shares in Electrosteel Castings and PTC India for Rs 207 Crore -
IndiGo Enhances Domestic Routes with Direct Chennai-Durgapur Flights -
Tesla to Recall Nearly 4,000 Cybertrucks Over Accelerator Pedal Fault -
Reliance, ONGC, Tata, Adanis: Energy Stocks Didn't Get The Memo Of Bears, Up 12% In 30-Days; 10 Stocks To BUY -
Sebi to Enhance Price Discovery for Firms Trading Below Book Value
Dr. Reddys Launches Oral Anti Covid 19 Drug; Shares Gain Over 1%
Dr. Reddy's shares shall be in focus in today's trade i.e. June 28, 2021 as the company has come up with the Covid 19 medicine 2 Deoxy D glucose (2 DG). The pricing of the drug has been fixed at Rs. 999 per sachet.
The scrip in early trade gained by a tad bit gaining 0.25% and hit a day's high price of Rs. 5363 per share. The scrip is over 3.7% percent away from its 52-week high price of Rs. 5515.
Earlier the pharma major said that the company is determining the pricing of the product i.e. an oral anti viral drug for Covid 19 patients. Also, the company said customers as well as Covid patients need to be cautious of agents selling fake drugs in the name of 2DG drug.
In an advisory, the Hyderabad-based company said, "2DG has not yet been launched in the market and price per sachet has not been announced.''
Price target for Dr. Reddy's
Average brokerage price target for the scrip is Rs. 5623.67 per share i.e. an upside of over 5 percent.
GoodReturns.in
